Twist Bioscience Corporation (TWST)
NASDAQ: TWST · IEX Real-Time Price · USD
53.90
+0.34 (0.63%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Twist Bioscience Revenue
Twist Bioscience had revenue of $277.49M in the twelve months ending March 31, 2024, with 21.79% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $75.30M with 25.13% year-over-year growth. In the fiscal year ending September 30, 2023, Twist Bioscience had annual revenue of $245.11M with 20.41% growth.
Revenue (ttm)
$277.49M
Revenue Growth
+21.79%
P/S Ratio
11.31
Revenue / Employee
$301,943
Employees
919
Market Cap
3.14B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
Sep 30, 2019 | 54.39M | 28.96M | 113.89% |
Sep 30, 2018 | 25.43M | 14.66M | 136.16% |
Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
Sep 30, 2016 | 2.27M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 6.54B |
Amedisys | 2.25B |
GoodRx Holdings | 764.16M |
Inari Medical | 520.66M |
iRhythm Technologies | 513.17M |
Amicus Therapeutics | 423.49M |
Denali Therapeutics | 295.39M |
ADMA Biologics | 283.18M |
TWST News
- 4 days ago - Twist Bioscience Announces Clinical Progression of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries - Business Wire
- 11 days ago - Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024 - Business Wire
- 12 days ago - Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies - Business Wire
- 13 days ago - Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A - Business Wire
- 6 weeks ago - Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor - Business Wire
- 6 weeks ago - Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety - Business Wire
- 2 months ago - Twist Bioscience to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications - Business Wire